

RECEIVED

AUG 28 2002

TECH CENTER 1600/2900

PATENT

Attorney Docket No.: 3951.224-US



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Thim et al.

Serial No.: 09/528,644

Group Art Unit: 1647

Filed: March 20, 2000

Examiner: David Romeo

For: Human Spasmolytic Polypeptide in Glycosylated Form

11/0  
M.J.  
9/5/02

**PRELIMINARY AMENDMENT**

Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

This Preliminary Amendment accompanies a Continued Prosecution Application under 37 C.F.R. 1.53(d). Claims 27-33, 36 and 39 are pending and were finally rejected in the Office Action dated March 18, 2002. The following amendments and remarks are therefore submitted to address the March 18, 2002 Office Action and reconsideration is respectfully requested in view of these amendments and remarks. Please amend the application as follows.

**IN THE SPECIFICATION:**

Please replace the paragraph at page 13, line 25 to page 14, line 6 with the following paragraph:

The 115 bp PCR fragment was digested with DdeI and then ligated to a 31 bp duplex formed from the oligonucleotides (GAGAAACCCTCCCCCTGCCAGTGCTCCAGGC) (SEQ ID NO:6) and (TCAGCCTGGAGCACTGGCAGGGGGAGGGTTCTC) (SEQ ID NO:7). The ligation product was amplified by PCR using forward primer 3 (GCTGAGAGATTGGAGAAGAGAGAGAAACCCTCCCCCT) (SEQ ID NO:8) and reverse primer 2. The 3' part of primer 3 is identical to the N-terminal encoding part of the HSP gene and the 5' part of primer 3 is identical to the C-terminal encoding part of the hybrid leader gene (Fig. 3).